Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
The New England Journal of Medicine|May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaAndreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
The New England Journal of Medicine|May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaAndreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Pageof 21